# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: James Madison (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN007-SYN-TD
- Date: 1774-04-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Josiah Pembroke-Achebe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for primary care visit for two years of recurrent sudden episodes of unresponsiveness, with low mood and anxiety, on levetiracetam started without a diagnosis. **S**

## Objective

PHQ-9: 13; GAD-7: 14; AUDIT-C: 1; Hemoglobin: 14.9 g/dL; White blood cells: 6.4 10*3/uL; Platelets: 231 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.86 mg/dL; eGFR: 125 mL/min/1.73 m²; Glucose: 84 mg/dL; Calcium: 9.6 mg/dL; TSH: 1.8 mIU/L; QTc: 404 ms. All results are synthetic.

BP 112/70 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 54 kg; BMI 19.1 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Recurrent sudden episodes of unresponsiveness for two years, two or three a month: he 'blanks out', stops speaking, slumps or sinks to the floor with his eyes closed for two to ten minutes, and afterwards is tearful and tired, with no tongue biting, incontinence, or injury; first during a period of overwork and little sleep at college; with low mood and anxiety; unchanged on levetiracetam; under evaluation for epilepsy, functional (dissociative) seizures, syncope, and other causes; Taking an antiseizure medicine (levetiracetam) started without a confirmed diagnosis of epilepsy. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEG **S**

## Plan

- Diagnostic workup: a detailed history including a witness account or phone video if available, ECG, blood count, metabolic panel, TSH, brain MRI with an epilepsy protocol, and inpatient video-EEG monitoring to capture his habitual events; levetiracetam continued unchanged until the evaluation is complete. Guideline: LaFrance WC Jr, et al. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia 2013;54(11):2005-2018 (PMID 24111933) (2013); Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025); Fisher RS, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia 2017;58(4):522-530 (PMID 28276060) (2017); Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-482 (PMID 24730690) (2014) **S**
- Safety now: no driving until the evaluation is complete and the neurologist advises; showers rather than baths, no swimming alone or working at heights; seizure first aid for the people he lives and works near. Guideline: Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025); First Aid for Seizures (2026) **S**
- Suicide risk assessment with a written safety plan: warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; the rifle locked with the ammunition stored separately; safety reviewed at every visit. Guideline: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**
- Neurology consultation (epilepsy and functional neurological disorder) with admission for video-EEG monitoring, on the diagnosis, the antiseizure medicine, and treatment. Guideline: LaFrance WC Jr, et al. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia 2013;54(11):2005-2018 (PMID 24111933) (2013); Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025); Fisher RS, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia 2017;58(4):522-530 (PMID 28276060) (2017) **S**
- Measurement-based care for depression and anxiety: PHQ-9 and GAD-7 at least monthly during treatment; psychotherapy, an SSRI such as sertraline, or both, by shared decision once the cause of the events is clear. Guideline: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022) **S**
- Driving: may resume once free of events for at least three months and with the neurologist's agreement, following state licensing rules and the AAN 1773 position. Guideline: Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025) **S**
